None listed
Conditions
Brief summary
Overview: The primary purpose of this study is to investigate the effect of moderate (MIE) as compared with high intensity exercise (HIE) on a number of outcomes related to the health of colorectal cancer survivors. Who is it for? You may be eligible to join this study if you are aged 18 years or over, and have finished treatment for colorectal cancer at least one month prior. Study details: Participants, will undertake baseline testing including a fitness test, blood sampling, a body composition scan and questionnaires. Participants will then be randomly allocated (by chance) to one of three exercise programs for 8 weeks. Exercise sessions will last approximately 40-50 minutes and be carried out 1-3 times per week, depending on the program allocated. The exercise will be in the form of stationary cycling. Patient outcomes will then be assessed through further fitness testing, blood sampling, body scan and questionnaires at 4 weeks into the program, at the end of the 8 week program and 4 weeks after the end of the exercise program. This study will be used to inform exercise prescription recommendations to enhance prognosis following colorectal cancer diagnosis and treatment.
Interventions
This project will investigate the feasibility and efficacy of high intensity exercise (HIE) as compared with moderate intensity exercise (MIE) on the insulin-like growth factor (IGF) axis, cardiorespiratory fitness, body composition and psychosocial health in colorectal cancer survivors. Study Design: This study is a three-arm, 12 week randomised controlled trial. Participants: Men and women who have been previously treated for colorectal cancer will be invited to participate in this randomised clinical trial. Intervention Structure: Following recruitment, participants will complete a familiarisation session, before which they will be provided with further details of the research program and afforded the opportunity to seek clarification for any questions related to the study. At the commencement of this session informed consent will be attained by way of a written consent form, witnessed by the principle investigator. The familiarisation session will conclude with a test of peak oxygen consumption (VO2peak test) After familiarisation, participants will complete a baseline testing session to measure all primary and secondary outcomes. Participants will then be randomised to one of three groups: (1) high intensity exercise - continuous (HIE-C) training group; (2) high intensity exercise - tapered (HIE-T) training group;(3) or a moderate intensity exercise (MIE) training group. The HIE-C and MIE groups will train at a frequency of 3 times per week for 8 weeks whereas the HIE-T group will train at a frequency of 3 times per week for the first 4 weeks, and at a frequency of once per week for the later 4 weeks. Participants will undergo testing at baseline (0 weeks), midpoint (4 weeks), endpoint (8 weeks) and follow-up (12 weeks). Participants will also be reassessed at further follow-up tests conducted at 6 and 12 months following the intervention. All exercise testing and training sessions will be supervised by an Accredited Exercise Physiologist (Exercise and Sports Science Australia). Participants will exercise in groups ranging from 1 to 4 depending on the suitability of times for each individual participant. Intervention: The HIE sessions will commence with 10 minutes of warm up at 50-70% of peak heart rate (HRpeak) before commencing 4 x 4 minute bouts of cycling at 85-95% HRpeak. Each 4 minute interval will be interspersed with a 3 minute period of active recovery at 50-70% HRpeak, totalling 38 minutes for the session. Attendance will be measured via a training log, and adherence to the prescribed exercise will be asssessed by continuous heart rate monitoring.
Sponsors
Study design
Eligibility
Inclusion criteria
i. Aged over 18 years old. ii. Greater than or equal to one-month post-treatment for colorectal cancer.
Exclusion criteria
i. Medicated with insulin or any insulin sensitising agents (biguanides, thiazolidinediones, sulfonylureas or meglitinides). ii. Any musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may prevent safe completion of the exercise demands of the study as determined by the research team and the participant's primary healthcare physician.